PENG vs. FIC Block for Hip Fracture ED Patients

Sponsor
Antonios Likourezos (Other)
Overall Status
Recruiting
CT.gov ID
NCT05102760
Collaborator
(none)
80
1
2
26.3
3

Study Details

Study Description

Brief Summary

Ultrasound-guided nerve blocks are an important tool for treating pain due to orthopedic injury in the ED. They provide long lasting, opioid-sparing pain relief that is generally safe and well-tolerated by patients1. Elderly patients with hip fractures commonly present to the ED, and their injury can be painful. Commonly used opioid pain regimens can have deleterious side effects, especially in elderly patients, like somnolence, delirium, hypotension and respiratory depression.

The fascia iliaca compartment (FIC) block has become a familiar technique to emergency physicians as a pain control treatment for hip fractures. The pericapsular nerve group (PENG) block has recently been proposed as a novel method to treat pain due to hip, acetabular and pelvic fracture by targeting the terminal sensory articular nerve branches of the femoral nerve (FN), obturator nerve (ON), and accessory obturator nerve (AON). At this time there has been no study comparing the efficacy of the two nerve blocks, PENG and FIC.

This aim of this study is to compare the efficacy of the PENG block (20mL of Bupivacaine 0.50%) to that of the FIC block (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED. Our hypothesis is that PENG will demonstrate analgesia that is non-inferior to FIC. Subjective pain scores on a scale of 0 to 10 will be assessed before and after the block. All subjects will receive 4mg of morphine after consent and prior to the block.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Nerve Block using FIC Proceedure
  • Procedure: Nerve Block using PENG Proceedure
N/A

Detailed Description

Ultrasound-guided nerve blocks are an important tool for treating pain due to orthopedic injury in the ED. They provide long lasting, opioid-sparing pain relief that is generally safe and well-tolerated by patients1. Elderly patients with hip fractures commonly present to the ED, and their injury can be painful. Commonly used opioid pain regimens can have deleterious side effects, especially in elderly patients, like somnolence, delirium, hypotension and respiratory depression.

The fascia iliaca compartment (FIC) block has become a familiar technique to emergency physicians as a pain control treatment for hip fractures. The pericapsular nerve group (PENG) block has recently been proposed as a novel method to treat pain due to hip, acetabular and pelvic fracture by targeting the terminal sensory articular nerve branches of the femoral nerve (FN), obturator nerve (ON), and accessory obturator nerve (AON). At this time there has been no study comparing the efficacy of the two nerve blocks, PENG and FIC.

This aim of this study is to compare the efficacy of the PENG block (20mL of Bupivacaine 0.50%) to that of the FIC block (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED. Our hypothesis is that PENG will demonstrate analgesia that is non-inferior to FIC. Subjective pain scores on a scale of 0 to 10 will be assessed before and after the block. All subjects will receive 4mg of morphine after consent and prior to the block.

A secondary aim is to show that the PENG block is preferable to the FIC block because it does not target motor nerves, thus preserving motor function allowing for an accurate neurological exam and hopefully providing for earlier ambulation. Also, we aim to determine if PENG block results in an significant reduction in amount of systemic pain medication needed for the patient.

This is a single-centered, prospective, randomized, blinded study involving patients who present to the ED with an isolated hip fracture. Patients who meet inclusion criteria will be consented for the study and then randomized to receive either a FIC block or a PENG block. Patients who are potentially to be enrolled in the study will receive standardized systemic analgesia while awaiting x-rays. If needed, patients will be administered morphine for breakthrough pain after the nerve blocks are placed. The exception to this standardization will be patients with a morphine allergy.

The research associate will screen for patients and confirm with the attending physician that the subject is eligible for enrollment and is able to give consent. The patient consented by a member of the research team, who will assess the patient's pain score on a scale of 0 to 10 prior to the block. The patient will then be randomized to receive either the FIC block or the PENG block to be performed by a member of the ultrasound faculty. The research associate will be blinded to the type of block being performed by the ultrasound faculty member. The research associate will then reassess the patient's pain score on the 0-10 scale at the 30 minute and 60-minute mark. They will also assess for any adverse events after the block is performed. The research associate will note the motor function in the quadriceps muscle 30 min and 60 min after the nerve block is placed. Any rescue medication given after the nerve block is placed in the ED will be recorded.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Pericapsular Nerve Group (PENG) Block vs. the Fascia Iliaca Compartment (FIC) Block for Patients With Isolated Hip Fractures in the Emergency Department
Actual Study Start Date :
Oct 20, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Fascia Iliaca Compartment

Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED

Procedure: Nerve Block using FIC Proceedure
Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure

Active Comparator: PENG Block

Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)

Procedure: Nerve Block using PENG Proceedure
Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure

Outcome Measures

Primary Outcome Measures

  1. Pain Score at 30 Minutes [30 minutes post administration of nerve block]

    The pain score at 11 point Likert Scale ranging 0 (no pain) to 10 (very severe pain) at 30 minutes post nerve block procedure

Secondary Outcome Measures

  1. Pain Score at 60 minutes [60 minutes post administration of nerve block]

    The pain score at 11 point Likert Scale ranging 0 (no pain) to 10 (very severe pain) at 60 minutes post nerve block procedure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 110 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult Emergency Medicine Patients over 18 years of age

  • Isolated hip fracture, intertrocanteric or more proximal

  • Pain score 5 or greater on a scale of 0 to 10 just prior to nerve block placement

Exclusion Criteria:
  • Patients with multi-system trauma

  • People who are unable to communicate their level of pain\

  • Pregnant patients

  • Pediatric Patients (less than 18 years of age)

  • Intoxicated Patients

  • Abnormal Vital Signs (HR>120bpm, MAP <65, Pulse Ox <95%)

  • Patients on long term systemic opioid analgesia

  • Allergy to amide local anesthetics

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maimonides Medical Center Brooklyn New York United States 11209

Sponsors and Collaborators

  • Antonios Likourezos

Investigators

  • Principal Investigator: Lawrence Haines, MD, Maimonides Medical Center

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Antonios Likourezos, Research Administration Director, Maimonides Medical Center
ClinicalTrials.gov Identifier:
NCT05102760
Other Study ID Numbers:
  • 2021-02-09
First Posted:
Nov 2, 2021
Last Update Posted:
Feb 3, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Antonios Likourezos, Research Administration Director, Maimonides Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2022